Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A VAN LINT

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
United European Gastroenterology Journal|June 2, 2021
Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapyPepijn W A Thomas, Tessa E H Römkens, Rachel L West, et al.
Expert Opinion on Drug Safety|January 23, 2023
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanerceptKimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, et al.
Expert Opinion on Drug Safety|July 25, 2024
The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of conceptJanneke M Quik, Helen R Gosselt, Jette A van Lint, et al.
Expert Opinion on Drug Safety|July 23, 2024
Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort studyBenthe H König, Helen R Gosselt, Jette A van Lint, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 3, 2023
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic MonitorJette A van Lint, Naomi T Jessurun, Sander W Tas, et al.
Drug Safety|February 4, 2021
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM RegistryEline L Giraud, Pepijn W A Thomas, Jette A van Lint, et al.
Expert Opinion on Drug Safety|February 16, 2023
Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseasesHelen R Gosselt, Jette A van Lint, Leanne J Kosse, et al.
Expert Opinion on Drug Safety|August 29, 2022
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort studyLieke H Roest, Leanne J Kosse, Jette A van Lint, et al.
Annals of the Rheumatic Diseases|December 17, 2021
Hypoglycaemia following JAK inhibitor treatment in patients with diabetesJette A van Lint, Florence P A M van Hunsel, Sander W Tas, et al.
Drug Safety|May 27, 2020
Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory DiseasesJette A van Lint, Naomi T Jessurun, Renske C F Hebing, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
United European Gastroenterology Journal|June 2, 2021
Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapyPepijn W A Thomas, Tessa E H Römkens, Rachel L West, et al.
Expert Opinion on Drug Safety|January 23, 2023
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanerceptKimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, et al.
Expert Opinion on Drug Safety|July 25, 2024
The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of conceptJanneke M Quik, Helen R Gosselt, Jette A van Lint, et al.
Expert Opinion on Drug Safety|July 23, 2024
Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort studyBenthe H König, Helen R Gosselt, Jette A van Lint, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 3, 2023
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic MonitorJette A van Lint, Naomi T Jessurun, Sander W Tas, et al.
Drug Safety|February 4, 2021
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM RegistryEline L Giraud, Pepijn W A Thomas, Jette A van Lint, et al.
Expert Opinion on Drug Safety|February 16, 2023
Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseasesHelen R Gosselt, Jette A van Lint, Leanne J Kosse, et al.
Expert Opinion on Drug Safety|August 29, 2022
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort studyLieke H Roest, Leanne J Kosse, Jette A van Lint, et al.
Annals of the Rheumatic Diseases|December 17, 2021
Hypoglycaemia following JAK inhibitor treatment in patients with diabetesJette A van Lint, Florence P A M van Hunsel, Sander W Tas, et al.
Drug Safety|May 27, 2020
Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory DiseasesJette A van Lint, Naomi T Jessurun, Renske C F Hebing, et al.
Pageof 3